Key result
High-dose methotrexate with citrovorum factor rescue and adriamycin resulted in tumor regression for >1 month in 53.8% (7/13) of children with metastatic osteogenic sarcoma.
Why the study?
Does high-dose methotrexate with citrovorum factor rescue and adriamycin induce tumor regression in children with metastatic osteogenic sarcoma?
Population
13 children with metastatic osteogenic sarcoma
Design
Case_series
Authors
Loading...
Should not yet change practice in metastatic osteogenic sarcoma; leaves open adjuvant potential pending controlled trials.
Observational (n=13)
Does high-dose methotrexate with citrovorum factor rescue and adriamycin induce tumor regression in children with metastatic osteogenic sarcoma?
High-dose methotrexate with citrovorum factor rescue and adriamycin showed tumor regression and symptom relief in children with metastatic osteogenic sarcoma, suggesting potential value as adjuvant therapy.
Rosen et al. (1974) conducted an observational in Metastatic osteogenic sarcoma (n=13). High-dose methotrexate with citrovorum factor rescue and adriamycin was evaluated on Tumor regression for greater than 1 month. High-dose methotrexate with citrovorum factor rescue and adriamycin resulted in tumor regression for >1 month in 53.8% (7/13) of children with metastatic osteogenic sarcoma.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: